FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models

Neuroscience

Volumn 202, Issue , 2012, Pages 396-404

  Bao, X Q ^a   Kong, X C ^a   Qian, C ^a   Zhang, D ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Akt; FLZ; MTOR; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; DOPAMINE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; N [2 (4 HYDROXYPHENYL)ETHYL] 2 (2,5 DIMETHOXYPHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN RTP801; S6 KINASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; BENZENEACETAMIDES; BLOTTING, WESTERN; CELL LINE; CHROMONES; CORPUS STRIATUM; DNA-BINDING PROTEINS; DOPAMINE; DOPAMINERGIC NEURONS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; MOVEMENT DISORDERS; MPTP POISONING; NEUROPROTECTIVE AGENTS; ONCOGENE PROTEIN V-AKT; PHENOLS; POSTURAL BALANCE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84863012412     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.11.036     Document Type: Article

References (33)

1. Aleyasin H., Rousseaux M.W., Marcogliese P.C., Hewitt S.J., Irrcher I., Joselin A.P., Parsanejad M., Kim R.H., Rizzu P., Callaghan S.M., Slack R.S., Mak T.W., Park D.S. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci U S A 2010, 107:3186-3191.
2. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28:166-172.
3. Bhaskar P.T., Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502.
4. Boland B., Nixon R.A. Neuronal macroautophagy: from development to degeneration. Mol Aspects Med 2006, 27:503-519.
5. Burke R.E. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007, 114:261-277.
6. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
7. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003, 991:1-14.
8. Feng W., Wei H., Liu G.T. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol Neurobiol 2005, 31:295-300.
9. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
10. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151.
11. Kong X.C., Zhang D., Qian C., Liu G.T., Bao X.Q. FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP(+). Brain Res 2011, 1383:99-107.
12. Levy O.A., Malagelada C., Greene L.A. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009, 14:478-500.
13. Lou H., Montoya S.E., Alerte T.N., Wang J., Wu J., Peng X., Hong C.S., Friedrich E.E., Mader S.A., Pedersen C.J., Marcus B.S., McCormack A.L., Di Monte D.A., Daubner S.C., Perez R.G. Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 2010, 285:17648-17661.
14. Malagelada C., Jin Z.H., Greene L.A. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 2008, 28:14363-14371.
15. Malagelada C., Jin Z.H., Jackson-Lewis V., Przedborski S., Greene L.A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 2010, 30:1166-1175.
16. Malagelada C., Ryu E.J., Biswas S.C., Jackson-Lewis V., Greene L.A. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci 2006, 26:9996-10005.
17. Marras C., Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008, 70:1996-2003.
18. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
19. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 1997, 73:45-48.
20. Meloni R., Biguet N.F., Mallet J. Post-genomic era and gene discovery for psychiatric diseases: there is a new art of the trade?. The example of the HUMTH01 microsatellite in the tyrosine hydroxylase gene. Mol Neurobiol 2002, 26:389-403.
21. Olanow C.W., Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005, 20(Suppl 11):S3-S10.
22. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002, 22:3090-3099.
23. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006, 103:18757-18762.
24. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
25. Steidinger T.U., Standaert D.G., Yacoubian T.A. A neuroprotective role for angiogenin in models of Parkinson's disease. J Neurochem 2011, 116:334-341.
26. Swiech L., Perycz M., Malik A., Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta 2008, 1784:116-132.
27. Tasaki Y., Omura T., Yamada T., Ohkubo T., Suno M., Iida S., Sakaguchi T., Asari M., Shimizu K., Matsubara K. Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. Brain Res 2010, 1344:25-33.
28. Thedieck K., Polak P., Kim M.L., Molle K.D., Cohen A., Jenö P., Arrieumerlou C., Hall M.N. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2007, 2:e1217.
29. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
30. Xiromerisiou G., Hadjigeorgiou G.M., Papadimitriou A., Katsarogiannis E., Gourbali V., Singleton A.B. Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci Lett 2008, 436:232-234.
31. Zhang D., Hu X., Wei S.J., Liu J., Gao H., Qian L., Wilson B., Liu G., Hong J.S. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinflammation 2008, 5:21.
32. Zhang D., Zhang J.J., Liu G.T. The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells. Neuropharmacology 2007, 52:423-429.
33. Zhang D., Zhang J.J., Liu G.T. The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells. Eur J Pharmacol 2007, 561:1-6.